Yao Han, Luo Xingxian, Zhang Hong, An Haiyan, Feng Wanyu, Feng Yi
Department of Anesthesiology, Peking University People's Hospital, Beijing, China.
Department of Pharmacy, Peking University People's Hospital, Beijing, China.
Front Pharmacol. 2021 Apr 30;12:646196. doi: 10.3389/fphar.2021.646196. eCollection 2021.
Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (-)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil. A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5-50 min) after subarachnoid puncture and before actual spinal anesthesia. R (-)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography-tandem mass spectrometry. R (-)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46-34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (-)-flurbiprofen concentration was significantly higher in plasma at all time points ( < 0.05) except at 30 or 40 min, and lower in CSF at all time points ( < 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (-)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC for R (-)-flurbiprofen was larger in plasma and smaller in CSF ( < 0.05 for both), and accordingly smaller CSF/plasma AUC ratio ( < 0.05). There was a positive correlation between R (-)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725, < 0.001) as well as in CSF (r = 0.718, < 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = -0.250, = 0.037), but not R (-)-flurbiprofen. Distribution of R (-)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (-)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen.
氟比洛芬酯是一种前体药物,通过酶促去除酯部分释放活性物质。它通过包裹在脂质微球载体中进行制剂,广泛用于治疗围手术期疼痛。在此,我们研究了静脉注射氟比洛芬酯后R(-)-和S(+)-氟比洛芬在人血浆和脑脊液(CSF)中的分布。总共70例接受脊髓麻醉下择期下肢手术的成年患者单次静脉注射100mg氟比洛芬酯。患者在蛛网膜下腔穿刺后和实际脊髓麻醉前的10个时间点(5 - 50分钟)被随机分为10组进行血浆和脑脊液采样。通过液相色谱 - 串联质谱法测定R(-)-和S(+)-氟比洛芬以及脑脊液/血浆比值。血浆中R(-)-氟比洛芬浓度范围为2.01至10.9μg/mL,脑脊液中为1.46 - 34.4ng/mL。血浆中S(+)-氟比洛芬浓度范围为1.18至10.8μg/mL,脑脊液中为2.53至47ng/mL。与S(+)-氟比洛芬相比,除30或40分钟外,R(-)-氟比洛芬在所有时间点的血浆浓度均显著更高(P < 0.05),除10、15和40分钟外,在所有时间点的脑脊液浓度均更低(P < 0.05)。校正体重指数后的药物浓度分析也显示血浆中R(-)-氟比洛芬浓度更高,脑脊液中更低。与S(+)-氟比洛芬相比,R(-)-氟比洛芬的血浆AUC更大,脑脊液AUC更小(两者均P < 0.05),因此脑脊液/血浆AUC比值更小(P < 0.05)。血浆中R(-)-氟比洛芬浓度与S(+)-氟比洛芬浓度呈正相关(r = 0.725,P < 0.001),脑脊液中也是如此(r = 0.718,P < 0.001),S(+)-氟比洛芬的血浆和脑脊液浓度呈负相关(r = -0.250,P = 0.037),但R(-)-氟比洛芬并非如此。R(-)-和S(+)-氟比洛芬在血浆和脑脊液中的分布差异显著。R(-)-氟比洛芬进入中枢神经系统的渗透率低于S(+)-氟比洛芬。